Drugs / HEC74647PA
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05504876 | Nov → Dec 2022 | — | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04201275 | Dec 2019 → Jan 2020 | chronic hepatitis C virus infection | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03673696 | Sep 2018 → Jul 2019 | chronic hepatitis C virus infection | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05395416 | Jun 2021 → Apr 2023 | chronic hepatitis C virus infection | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEC74647PA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03673696 ↗ |
| Known as | HEC74647 | “The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected Subjects” NCT04201275 ↗ |
| Route | Oral | “Capsule administered orally once daily” NCT03673696 ↗ |